Fig. 7
Scavenging mitochondrial ROS rescues chemo-immune-resistance in immuno-xenografts. 1 × 106 C/EBP-β LAP-overexpressing cells were injected subcutaneously in Hu-CD34+NSG mice. When tumor reached the volume of 50 mm3, animals (n = 6/group) were randomized and treated for 6 weeks as it follows: 1) vehicle (ctrl) group, treated with 0.1 ml saline solution intravenously (i.v.), once a week; 2) cisplatin (PT) group, treated with 2 mg/kg cisplatin i.v., once a week; 3) mitoquinol (mQ) group, treated with 100 mg/kg daily via oral gavage; 4) cisplatin + mitoquinol (PT + mQ) group, treated with 2 mg/kg cisplatin i.v., once a week. and 100 mg/kg mitoquinol daily via oral gavage. To induce LAP intratumourally, 1 mg/ml doxycycline was added daily to the drinking water (LAP+ mice). a Tumor growth was monitored by caliper. ***p < 0.001: LAP+PT + mQ-group vs. LAP−ctrl-group; °°°p < 0.001: LAP+ T + mQ-group vs LAP+ctrl-group; ###p < 0.001: LAP+PT + mQ-group vs LAP+PT-group (weeks 2–7). b Representative photographs of tumors from each group of treatment. c Representative immunohistochemical microphotographs of hematoxylin/eosin (HE) stained sections, sections immunostained for the pimonidazole hypoxic-probe or for the indicated proteins (63× objective, 20× ocular). Bar: 50 μm. d Percentage of intratumor Vγ9δ2 T-lymphocytes among all CD3+T-lymphocyte-infiltrating cells, measured by flow cytometry. Data are means±SD (n = 6 tumors). *p < 0.05,***p < 0.001: LAP+PT + mQ-group vs. LAP−ctrl-group; °p < 0.05,°°°p < 0.001: LAP+mQ/PT + mQ-group vs LAP+ctrl-group; ###p < 0.001: LAP+PT + mQ-group vs LAP+PT-group